Clinical Response Observation on Lamivudine to 84 Patients with Chronic Hepatitis B

Objective: to research Lamivudine's efficacy and safety on chronic Hepatitis B patients with HBV -2DNA positive. Methods:classifying the 84 patients into Lamivudine treatment group (43 patients) and control group (41 patients); treatment group taking 100mg Lamivudine orally per day for one year, and liver protecting, receding jaundice and reducing enzyme measures on control group. Results: 67.77% of treatment group patients' HBV-DNA turning to negative and final negative-conversion rate reaching 67.44% ; accumulative negative-conversion rate of control group being 14.63%, final negative-conversion rate 9.76; the efficacy comparison of the two groups P 0.01. For patients with high ALT before treatment, 77.14% patients in treatment group returns to normal after 52 weeks treatment, 18.18% in control group, P 0.01. HBeAg negative-conversion rate of treatment group after 52 weeks' treatment is 40%, 7.14% in control group, P 0.05. Comparing side effects incidence, no significant difference is found P 0.05. Conclusion:Lamivudine can visibly reduce HBV-DNA in serum and restore ALT to normal with few side effects and good tolerance.